Ascentage Pharma Group International (AAPG) Operating Leases (2023 - 2025)

Ascentage Pharma Group International's Operating Leases history runs 4 years deep, the most recent figure standing at $3.1 million for Q4 2025.

• In Q4 2025, Operating Leases fell 25.64% year-over-year to $3.1 million; the TTM figure through Dec 2025 stood at $3.1 million (down 25.64% YoY), while the FY2025 annual figure was $3.2 million, down 26.58% from the prior year.
• Operating Leases for Q4 2025 stood at $3.1 million, down from $4.2 million in the prior quarter.
• The five-year high for Operating Leases was $4.2 million in Q4 2024, with the low at $2.4 million in Q4 2022.
• The 4-year median for Operating Leases is $3.1 million (2025), against an average of $3.2 million.
• The sharpest annual moves came in 2024 and 2025: Operating Leases jumped 33.61% in 2024, then declined 25.64% in 2025.
• Ascentage Pharma Group International's Operating Leases stood at $2.4 million in 2022, then soared by 30.09% to $3.2 million in 2023, then soared by 33.61% to $4.2 million in 2024, then slipped by 25.64% to $3.1 million in 2025.
• Business Quant data shows AAPG's Operating Leases at $3.1 million in Q4 2025, $4.2 million in Q4 2024, and $3.2 million in Q4 2023.